一分钟看懂
这是一项关于卵巢癌的II 期研究，登记的药物或干预包括Trastuzumab Rezetecan (SHR-A1811)；Bevacizumab；Platinum-based chemotherapy，当前状态为尚未开始招募。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Trastuzumab Rezetecan (SHR-A1811)；Bevacizumab；Platinum-based chemotherapy · II 期
登记条件中文摘要
登记的基本范围为女性，年龄18 岁至75 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Cancer Hospital & Institute · 北京
公开的入选条件
- 1. Voluntarily agree to participate in the study, provide written informed consent, demonstrate good compliance, and be able to cooperate with protocol-required follow-up visits.
- 2. Female patients aged 18 to 75 years old (inclusive, calculated from the date of signing the informed consent form).
- 3. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (mucinous carcinoma is excluded).
- 4. Received 1 to 2 prior lines of systemic therapy and must have received prior PARP inhibitor therapy.
- 5. Partially platinum-sensitive recurrence, defined as disease recurrence occurring ≥6 months but \<12 months after the completion of the last platinum-containing therapy:
- Neoadjuvant and/or adjuvant therapy are combined and counted as 1 line of therapy;
- Maintenance therapy does not count as a separate line of therapy;
- Changes in treatment regimens due to reasons other than disease progression (such as intolerable toxicity) are considered part of the same line of therapy and are not counted separately.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07843303；登记信息更新于 2026-10-01。